Aravis Ventures
32
21M
19
1.45
7
0.41
10
- Stages of investment
- Areas of investment
Summary
In 2001 was created Aravis Ventures, which is appeared as VC. The main office of represented VC is situated in the Zu00fcrich. The company was established in Europe in Switzerland.
Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Health Care, Pharmaceutical. The fund has no exact preference in some founders of portfolio startups. If startup sums 3 or 5+ of the founder, the chance for it to be financed is low. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Ikaria, Kalypsys, MerLion Pharma.
The high activity for fund was in 2009. Despite it in 2019 the fund had an activity. Deals in the range of 10 - 50 millions dollars are the general things for fund. This Aravis Ventures works on 3 percentage points more the average amount of lead investments comparing to the other organizations. Considering the real fund results, this VC is 9 percentage points more often commits exit comparing to other organizations. The fund is generally included in less than 2 deals every year. The higher amount of exits for fund were in 2015.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Aravis Ventures, startups are often financed by Novartis Venture Fund, 5AM Ventures, Versant Ventures. The meaningful sponsors for the fund in investment in the same round are Versant Ventures, M Ventures, Dansk Innovation. In the next rounds fund is usually obtained by Novartis Venture Fund, Dansk Innovation, 5AM Ventures.
This organization was formed by Jean-Philippe Tripet, Simon Nebel. The overall number of key employees were 5.
Investments analytics
Analytics
- Total investments
- 32
- Lead investments
- 7
- Exits
- 10
- Rounds per year
- 1.45
- Follow on index
- 0.41
- Investments by industry
- Biotechnology (32)
- Health Care (15)
- Therapeutics (15)
- Medical (10)
- Pharmaceutical (9) Show 7 more
- Investments by region
-
- Switzerland (14)
- United States (12)
- Singapore (3)
- Denmark (1)
- Germany (1) Show 1 more
- Peak activity year
- 2009
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 18
- Avg. valuation at time of investment
- 156M
- Group Appearance index
- 1.00
- Avg. company exit year
- 8
- Avg. multiplicator
- 3.59
- Strategy success index
- 0.70
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Evolva | 11 Dec 2009 | Biotechnology, Food and Beverage, Health Care, Wellness, Consulting | Early Stage Venture | 17M | Switzerland, Aargau |
| 30 Oct 2002 | Biotechnology, Pharmaceutical | Early Stage Venture | 13M | Singapore, Singapore |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.